MCID: CRV002
MIFTS: 42

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 74
Cervical Intraepithelial Neoplasia 45 74
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 74
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8991
ICD9CM 36 233.1
MeSH 45 D018290
NCIt 51 C4000
ICD10 34 D06 D06.9

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the uterine cervix.

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to squamous cell papilloma and cervical intraepithelial neoplasia. An important gene associated with Cervix Uteri Carcinoma in Situ is SERPIND1 (Serpin Family D Member 1), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Oncogene Induced Senescence. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and breast, and related phenotype is mortality/aging.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.3 CDKN2A TP53
2 cervical intraepithelial neoplasia 31.2 CDKN2A KRT17 TERC
3 cervicitis 31.0 CDKN2A SERPIND1
4 anogenital venereal wart 30.8 CDKN2A GP6 TP53
5 chronic cervicitis 30.5 GP6 SERPIND1
6 cervix carcinoma 30.4 CDKN2A TP53
7 suppressor of tumorigenicity 3 30.3 CDKN2A TP53
8 in situ carcinoma 30.0 CDKN2A KRT17 SERPIND1 TP53
9 papilloma 10.8
10 adenocarcinoma 10.5
11 chlamydia 10.5
12 bacterial vaginosis 10.4
13 human immunodeficiency virus infectious disease 10.4
14 cervical squamous cell carcinoma 10.4
15 adenocarcinoma in situ 10.4
16 cervical cancer 10.3
17 retinoblastoma 10.3
18 herpes simplex 10.3
19 balanoposthitis 10.3 CDKN2A GP6
20 bladder squamous cell carcinoma 10.3 CDKN2A TP53
21 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
22 spitz nevus 10.3 CDKN2A TP53
23 bladder carcinoma in situ 10.3 CDKN2A TP53
24 scrotal carcinoma 10.3 CDKN2A TP53
25 thyroid lymphoma 10.3 CDKN2A TP53
26 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
27 bartholin's gland disease 10.3 CDKN2A TP53
28 anal squamous cell carcinoma 10.3 CDKN2A TP53
29 megaesophagus 10.3 CDKN2A TP53
30 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
31 gastric adenosquamous carcinoma 10.3 CDKN2A TP53
32 oral leukoplakia 10.3 CDKN2A TP53
33 meningeal melanomatosis 10.3 CDKN2A TP53
34 dedifferentiated liposarcoma 10.3 CDKN2A TP53
35 endocervical adenocarcinoma 10.3 CDKN2A TP53
36 cervix small cell carcinoma 10.3 CDKN2A TP53
37 necrotizing sialometaplasia 10.2 CDKN2A TP53
38 verrucous carcinoma 10.2 CDKN2A TP53
39 tongue disease 10.2 CDKN2A TP53
40 optic nerve neoplasm 10.2 CDKN2A TP53
41 juvenile pilocytic astrocytoma 10.2 CDKN2A TP53
42 cervical adenosarcoma 10.2 GP5 GP6
43 eccrine sweat gland neoplasm 10.2 KRT17 TP53
44 tonsil cancer 10.2 CDKN2A TP53
45 vulva cancer 10.2 CDKN2A TP53
46 barrett's adenocarcinoma 10.2 CDKN2A TP53
47 herpangina 10.2 GP5 GP6
48 ampulla of vater cancer 10.2 KRT17 TP53
49 oropharynx cancer 10.2 CDKN2A TP53
50 anus disease 10.2 CDKN2A GP5

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.28 CDKN2A CINP COL27A1 GP6 INSM1 KLHL40

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 99011-02-6 57469
2
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
3
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
4
Tamoxifen Approved Phase 3 10540-29-1 2733526
5
Sodium Citrate Approved, Investigational Phase 3 68-04-2
6
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
13
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
14
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
15
Floxuridine Approved Phase 2, Phase 3 50-91-9 5790
16
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
17
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
18
Heparin Approved, Investigational Phase 2, Phase 3 9005-49-6 46507594 772
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
20
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
22
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
24
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
25
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
26
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
27
Doxil Approved June 1999 Phase 3,Phase 2 31703
28 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
29 Antirheumatic Agents Phase 3,Phase 2,Early Phase 1
30 Anti-Inflammatory Agents Phase 2, Phase 3,Early Phase 1
31 Peripheral Nervous System Agents Phase 2, Phase 3,Early Phase 1
32 interferons Phase 2, Phase 3,Phase 1,Not Applicable
33 Interferon Inducers Phase 2, Phase 3,Phase 1,Not Applicable
34 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1,Not Applicable
35 Vaccines Phase 3,Phase 1,Phase 2,Not Applicable
36 Immunoglobulins Phase 3,Phase 1
37 Antibodies Phase 3,Phase 1
38 Protein Kinase Inhibitors Phase 3,Phase 2
39 Mitogens Phase 3,Phase 2
40 Antineoplastic Agents, Immunological Phase 3,Phase 2
41 Antineoplastic Agents, Hormonal Phase 3,Phase 2
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
43 Estrogen Receptor Antagonists Phase 3,Phase 2
44 Steroid Synthesis Inhibitors Phase 3,Phase 2
45 Citrate Phase 3
46 Selective Estrogen Receptor Modulators Phase 3
47 Estrogens Phase 3,Phase 2
48 Bone Density Conservation Agents Phase 3
49 Hormone Antagonists Phase 3,Phase 2
50 Aromatase Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
2 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
3 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
4 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
5 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
6 Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Completed NCT00237562 Phase 3
7 Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study Completed NCT00929526 Phase 3
8 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
9 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed NCT00045032 Phase 3 Herceptin;Herceptin
10 Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects Completed NCT00937950 Phase 3
11 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
12 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
13 REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Recruiting NCT03185013 Phase 3
14 REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Recruiting NCT03721978 Phase 3
15 Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi Recruiting NCT03897088 Phase 3 Tildrakizumab;Placebo
16 EPA for Metastasis Trial 2 Recruiting NCT03428477 Phase 3 Icosapent Ethyl
17 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
18 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
19 Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer Not yet recruiting NCT02529774 Phase 2, Phase 3 Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6);Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
20 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis Not yet recruiting NCT03897075 Phase 3 Tildrakizumab;Placebo
21 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
22 Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Completed NCT02195089 Phase 1, Phase 2 BLS_ILS_E710c 500mg;BLS_ILB_710c 1000mg;BLS_ILS_E710c 1500mg
23 Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia Completed NCT02139267 Phase 2
24 A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Completed NCT01304524 Phase 2
25 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00054041 Phase 2
26 SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia Completed NCT00075569 Phase 2
27 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Completed NCT00081263 Phase 2 Celecoxib
28 A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection Completed NCT01022346 Phase 2 Placebo;RO5217790
29 A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions. Completed NCT02976987 Phase 2 Cidofovir
30 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00121173 Phase 1, Phase 2
31 Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) Completed NCT00365378 Phase 2
32 Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine Completed NCT00316693 Phase 2
33 A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. Completed NCT00717405 Phase 2 Standard chemotherapy;bevacizumab [Avastin];trastuzumab [Herceptin]
34 A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia Recruiting NCT01925378 Phase 2 Nelfinavir
35 IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 Recruiting NCT03267680 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
36 Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions Recruiting NCT03233412 Phase 2 Imiquimod
37 PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Recruiting NCT01723774 Phase 2 PD0332991;Anastrozole;Goserelin
38 Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) Active, not recruiting NCT02596243 Phase 2
39 Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery Active, not recruiting NCT00436566 Phase 2 cyclophosphamide;doxorubicin hydrochloride;lapatinib ditosylate;paclitaxel
40 S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix Withdrawn NCT00072540 Phase 2 celecoxib
41 Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 Completed NCT01634503 Phase 1
42 Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia Recruiting NCT00788164 Phase 1 imiquimod
43 Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Not yet recruiting NCT03676101 Phase 1
44 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
45 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Unknown status NCT02554344 Early Phase 1 Curcumin
46 Follow-up of Abnormal and Inadequate Smear-test Results Unknown status NCT02002468 Not Applicable
47 Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer Unknown status NCT01371695
48 Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia Unknown status NCT02406352 Not Applicable
49 HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN Unknown status NCT01058460 Not Applicable
50 DNA Methylation Biomarkers for Cervical Cancer Screening Unknown status NCT02605941

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

42
Cervix, Testes, Breast, Liver, Bone, Prostate, Nk Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Uteri Carcinoma in Situ:

20
The Uterine Cervix

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

# Title Authors Year
1
Koilocytosis preceding squamous cell carcinoma in situ of uterine cervix. ( 3028122 )
1987
2
LYMPHATIC SPREAD OF CARCINOMA-IN-SITU OF UTERINE CERVIX. ( 14087268 )
1963
3
Carcinoma in situ of uterine cervix. ( 13594660 )
1958
4
Carcinoma in situ of uterine cervix. ( 13594664 )
1958

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.62 CDKN2A CINP INSM1 TP53
2 blood coagulation GO:0007596 9.43 GP5 GP6 SERPIND1
3 positive regulation of cell cycle arrest GO:0071158 9.16 INSM1 TP53
4 replicative senescence GO:0090399 8.96 CDKN2A TP53
5 hemostasis GO:0007599 8.8 GP5 GP6 SERPIND1

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Cervix Uteri Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....